Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Transforming growth factor beta (TGF-β) isoforms (TGF-β1, -β2, -β3) are key cytokines involved in critical cancer processes.
• These processes include tumor cell invasion, migration, angiogenesis, immunosuppression, and regulation of tumor stem cell properties.
• Targeting TGF-β signaling pathways presents a potential therapeutic strategy for solid tumors.

Purpose of the Study:

• To identify and develop potent and selective antisense oligodeoxynucleotides (ASOs) for TGF-β isoform suppression.
• To evaluate the efficacy of these ASOs in preclinical cancer models.

Main Methods:

• Development of chemically modified antisense oligodeoxynucleotides, specifically fully phosphorothioate locked nucleic acid (LNA) gapmers.
• Testing of ASO efficacy in cell-based assays for TGF-β isoform suppression.
• In vivo evaluation of ASOs in preclinical models of solid tumors.

Main Results:

• Identification and selection of highly potent and selective ASOs targeting TGF-β isoforms.
• Demonstration of effective and selective suppression of TGF-β isoform expression in cell-based assays.
• Validation of ASO efficacy in preclinical in vivo models.

Conclusions:

• Chemically modified antisense oligodeoxynucleotides, particularly LNA gapmers, are effective tools for TGF-β isoform suppression.
• These ASOs show promise as a therapeutic strategy for treating solid tumors by targeting key oncogenic pathways.
• Further development of these ASOs could lead to novel cancer treatments.